Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$427K Buy
23,806
+2,360
+11% +$43K ﹤0.01% 3194
2024
Q2
$377K Sell
21,446
-2,129
-9% -$44K ﹤0.01% 3237
2024
Q1
$605K Buy
23,575
+5,655
+32% +$142K ﹤0.01% 2941
2023
Q4
$467K Sell
17,920
-3,210
-15% -$73.3K ﹤0.01% 2998
2023
Q3
$487K Sell
21,130
-6,791
-24% -$170K ﹤0.01% 2909
2023
Q2
$655K Buy
27,921
+75
+0.3% +$1.27K ﹤0.01% 2754
2023
Q1
$331K Buy
+27,846
New +$397K ﹤0.01% 3178

Other funds holding XP

Raymond James & Associates's XP Position: Q3 2024 in Review

Raymond James & Associates increased its XP (XP) stake by 11% in Q3 2024, buying an estimated $43K and bringing the position to 23,806 shares worth $427K. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

Raymond James & Associates first reported a position in XP in Q1 2023 and has held it in 7 quarters since. The position peaked at $655K in Q2 2023. 292 funds tracked by Wall St. Rank hold XP as of Q3 2024.

  • Raymond James & Associates held 23,806 shares of XP worth $427K as of Q3 2024.
  • Raymond James & Associates bought 2,360 XP shares in Q3 2024, an estimated $43K.
  • XP made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3194 holding.
  • Raymond James & Associates first reported a position in XP in Q1 2023 and has held it in 7 quarters since.
  • Raymond James & Associates's XP position peaked at $655K in Q2 2023.
  • 292 funds tracked by Wall St. Rank held XP as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.